I am a
Home I AM A Search Login

Papers of the Week

2023 Jan 01

Allergy Asthma Proc



Current and future management of chronic spontaneous urticaria and chronic inducible urticaria.


Do TT, Canty EA, Joshi SR
Allergy Asthma Proc. 2023 Jan 01; 44(1):3-14.
PMID: 36719690.


Chronic urticaria (CU), characterized by ≥6 weeks of intense pruritus, remains a debilitating condition for patients. New and safe treatments are needed to manage CU recalcitrant to standard therapy. A review of the current literature of standard and novel therapeutics in the management of CU was conducted. A literature search via a medical literature data base and clinical trial data base was conducted to identify treatment options for CU and current clinical trials. Second-generation antihistamines, omalizumab, and cyclosporine remain the most proven therapeutic options for CU. Dupilumab, mepolizumab, benralizumab, tezepelumab, and CDX-0159 are all undergoing clinical trials for CU. Although ligelizumab demonstrated initial promising results, a phase III study was discontinued due to a nonsuperior clinical impact compared with omalizumab. Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.